ACS chemical neuroscience molecule spotlight on Sabril

Research output: Contribution to journalShort survey

2 Scopus citations

Abstract

Sabril (vigabatrin) oral solution was approved by the FDA on August 21st, 2009 for treatment of infantile spasms in children ages 1 month to 2 years and complex partial seizures in adults (tablets).

Original languageEnglish (US)
Number of pages1
JournalACS Chemical Neuroscience
Volume1
Issue number7
DOIs
Publication statusPublished - Jul 21 2010

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this